A real problem that makes rheumatologists have few opportunities to use biological agents is the price that far exceeds that of methotrexate. One of the hottest topics in rheumatology is to establish if this greater value is cost-effective.
A national experience in effectiveness and safety is being formed in those centers that participate as collaborators in international clinical research studies with drugs and biological drugs in rheumatoid arthritis Flekosteel.
No comments:
Post a Comment